[FXa inhibitor].
Kunitada
S
S
Global Medical Planning Department, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan. Kunitpm0@daiichipharm.co.jp
D000818:Animals; D000925:Anticoagulants; D015195:Drug Design; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008970:Molecular Weight; D009281:Naphthalenes / Q000494:pharmacology; D011422:Propionates / Q000494:pharmacology; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors / Q000502:physiology; D000077022:Survivin
C086910:(2S)-2-(4-(((3S)-1-acetimidoyl-3-pyrrolidinyl)oxy)phenyl)-3-(7-amidino-2-naphtyl)propanoic acid; D000925:Anticoagulants; C107489:BIRC5 protein, human; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D051034:Inhibitor of Apoptosis Proteins; D009281:Naphthalenes; D011422:Propionates; D011956:Receptors, Cell Surface; D000077022:Survivin